The Effect Of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor For Primary Prevention Of Neutropenia After Chemotherapy In Ovarian Cancer

Objective:This study retrospectively analyzed the incidence of neutropenia in ovarian cancer patients who prophylactically received pegylated recombinant human granulocyte colony stimulating factor(PEG-rh G-CSF)during chemotherapy.To provide clinical experience for the prevention and management of neutropenia after chemotherapy in gynecological malignant tumors and to clarify the effect of PEG-rh G-CSF in the primary prevention of neutropenia after chemotherapy.Methods:We retrospectively analyzed the medical records of 65 patients with ovarian cancer who received chemotherapy in our hospital from January 1,2017 to December 31,2020.Patients were divided into two groups according to the use of Granulocyte colony stimulating factor(G-CSF).Observation group: PEG-rh G-CSF was given to the patients prophylacticly in each chemotherapy cycle after 48 hours of chemotherapy.Control group:PEG-rh G-CSF was not routinely used,and Recombinant human granulocyte colony stimulating factor(rh G-CSF)was given to the patients with leukopenia after chemotherapy.The incidence of grade 3 and 4 neutropenia and the incidence of neutropenia before the next cycle of chemotherapy were compared between the two groups.SPSS25.0 software was used for statistical analysis.The measurement data were described by mean±standard deviation,and independent sample t-test was used for comparison between groups.The counting data were expressed by the number of cases and the rate,and the chi-square test was used to compare the rates between the two groups.P <0.05 was regarded as statistically significant.Results: A total of 65 cases were included in this study,including 34 cases in the observation group and 31 cases in the control group.The average age of the patients in the observation group was 55.59(±9.29)years.The total course of chemotherapy was 205(4-10 courses).The ANC baseline before chemotherapy was 6.685(±2.008)× 10 ^ 9 / L.The average age of patients in the control group was 52.13(±11.29)years.The total course of chemotherapy was 213 courses(5-9 courses).The ANC baseline before chemotherapy was 6.911(±2.206)× 10 ^ 9 / L.Patients in both groups received paclitaxel or doxorubicin liposomes combined with carboplatin chemotherapy.There was no significant difference in age,stage,chemotherapy regimen and ANC baseline before chemotherapy.The incidence of grade 3 and 4 neutropenia in the observation group(6.3%)was significantly lower than that in the control group(17.4%),the difference was statistically significant(P < 0.05);the incidence of neutropenia before the next cycle of chemotherapy(21.6%)was significantly lower than that in the control group(36.3%),the difference was statistically significant(P < 0.05),and grade 3 or 4neutropenia was not occurred in the observation group before the next cycle of chemotherapy.The incidence of grade 1 and 2 neutropenia in the observation group(34.6%)was lower than that in the control group(39.4%),but the difference was not statistically significant(P > 0.05).Febrile neutropenia did not occur in both groups.Conclusions:The prophylactic application of PEG-rh G-CSF can significantly reduce the occurrence of neutropenia in ovarian cancer patients during chemotherapy,reduce the decrease in ANC before the next cycle of chemotherapy,and ensure that patients can complete chemotherapy on time.PEG-rh G-CSF can be used to prevent and manage the occurrence of chemotherapy-induced neutropenia in gynecological malignant tumors in clinical work.